| References: |
L-755,507 enhance CRISPR-mediated HDR efficiency, 3-fold for large fragment insertions and 9-fold for point mutations. L-755,507 was previously characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 ~0.43 nM. It has > 1000 fold selectivity overβ1- and β2-adrenoceptors (EC50 ~ 580 nM and >10000 nM for β1- and β2-adrenoceptors respectively). It stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM).In vitro: L-755,507 was used at 1-5 µM final concentration in various in vitro assays.In vivo: L-755,507 stimulates metabolic rate by 30% after acute bolus intravenous administration of 0.1 mg/kg to rhesus monkeys. For the detailed information of L-755,507, the solubility of L-755,507 in water, the solubility of L-755,507 in DMSO, the solubility of L-755,507 in PBS buffer, the animal experiment (test) of L-755,507, the cell expriment (test) of L-755,507, the in vivo, in vitro and clinical trial test of L-755,507, the EC50, IC50,and affinity,of L-755,507, For the detailed information of L-755,507, the solubility of L-755,507 in water, the solubility of L-755,507 in DMSO, the solubility of L-755,507 in PBS buffer, the animal experiment (test) of L-755,507, the cell expriment (test) of L-755,507, the in vivo, in vitro and clinical trial test of L-755,507, the EC50, IC50,and affinity,of L-755,507, Please contact DC Chemicals. |
